Saturday, 16 February 2019

Firm finds way past CBD morass by using other botanicals that target endocannabinoid system –

Jade Beutler, CEO of Emerald Health Bioceuticals, said the expertise of parent company Emerald Health Sciences in the Canadian cannabis trade led to his division’s line of supplements that comply with US regulations.

Cannabis expertise formed backbone

“Our parent company sells and distributes medical marijuana and recreational products in Canada,”​ Beutler told NutraIngredients-USA.

“We are steeped in this. The endocannabinoid system is something we know a lot about and have a lot of interest in. We also have a pharmaceutical company, which is not a sham operation,”​ he said.

“We have something like 15 cannabis related businesses. We have as much as 2 million square feet under grow indoors, and more in open fields,”​ Beutler said.

Beutler said the leaders of the parent company had approached him to consult on ways to use Emerald’s acquired expertise in the US market, perhaps with a line of CBD supplements.  Beutler has a long history in the nutritional and therapeutic product industries, which included a stint as CEO of Barleans Oils.

Beutler said his response was unequivocal.

“I told them ​[CBD is] not legal in the US and I didn’t think it was going to be legal anytime soon,” ​he said. “I decided it was not a risk I wanted to take personally.”

In researching the product development opportunities in the US, Beutler said he had access to Emerald’s scientific advisory board, which he said includes some of the world’s leading experts on cannabinoids and their actions in the body. Those include Giovanni Appendino, PhD, of the Università del Piemonte Orientale in Novara, Italy. Appendino has more than 20 papers published on the endocannabinoid system.

« »